Boston Scientific (NYSE:BSX) Stock Price Target Cut by Barclays

Key Points

• Barclays cut Boston Scientific’s price target from $48 to $45 while maintaining an “equal weight” rating, implying about 4.5% upside from the stock’s $43.05 price.
• Analyst sentiment has weakened, with JPMorgan, Oppenheimer and others lowering ratings or targets; however, the broader consensus remains “Moderate Buy” with a $61.43 target price.
• Boston Scientific’s latest results met EPS estimates at $0.73 and beat revenue expectations with $5.14 billion, but weaker margins, operational disruptions and reduced guidance have raised concerns about near-term growth.

Boston Scientific (NYSE:BSX - Get Free Report) had its target price decreased by equities researchers at Barclays from $48.00 to $45.00 in a report released on Friday, Benzinga reports. The firm currently has an "equal weight" rating on the medical equipment provider's stock. Barclays's price objective indicates a potential upside of 4.54% from the stock's current price.

Other equities research analysts also recently issued reports about the company. Stifel Nicolaus decreased their price target on Boston Scientific from $60.00 to $55.00 and set a "buy" rating for the company in a report on Monday. JPMorgan Chase & Co. cut shares of Boston Scientific from an "overweight" rating to a "neutral" rating and set a $46.00 target price for the company. in a research note on Wednesday. Truist Financial dropped their price target on shares of Boston Scientific from $57.00 to $51.00 and set a "buy" rating on the stock in a research note on Wednesday, October 14th. Oppenheimer downgraded shares of Boston Scientific from an "outperform" rating to a "market perform" rating in a research report on Thursday. Finally, Wells Fargo & Company lowered their price objective on Boston Scientific from $48.00 to $45.00 and set an "equal weight" rating on the stock in a report on Thursday. One analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating, eight have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, Boston Scientific has an average rating of "Moderate Buy" and a consensus target price of $61.43.

Boston Scientific Stock Performance

NYSE BSX traded up $0.36 on Friday, reaching $43.05. The stock had a trading volume of 2,504,092 shares, compared to its average volume of 18,660,322. The business's 50-day moving average price is $44.93 and its 200 day moving average price is $57.15. The stock has a market cap of $62.38 billion, a P/E ratio of 18.20, a price-to-earnings-growth ratio of 1.04 and a beta of 0.58. Boston Scientific has a 12-month low of $39.57 and a 12-month high of $105.65. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.74 and a current ratio of 1.24.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings data on Wednesday, October 28th. The medical equipment provider reported $0.73 EPS for the quarter, meeting analysts' consensus estimates of $0.73. The company had revenue of $5.14 billion for the quarter, compared to analyst estimates of $5.09 billion. Boston Scientific had a net margin of 16.62% and a return on equity of 18.73%. Boston Scientific's quarterly revenue was up 1.4% on a year-over-year basis. During the same period in the previous year, the business posted $0.75 earnings per share. As a group, equities analysts expect that Boston Scientific will post 3.18 earnings per share for the current year.

Insider Buying and Selling

In other news, Director David C. Habiger bought 2,100 shares of the stock in a transaction on Wednesday, August 5th. The shares were bought at an average price of $47.59 per share, with a total value of $99,939.00. Following the completion of the acquisition, the director owned 17,160 shares of the company's stock, valued at approximately $816,644.40. This trade represents a 13.94% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Michael F. Mahoney purchased 186,240 shares of the company's stock in a transaction dated Monday, August 3rd. The stock was purchased at an average price of $48.33 per share, with a total value of $9,000,979.20. Following the transaction, the chief executive officer owned 1,590,024 shares of the company's stock, valued at approximately $76,845,859.92. This represents a 13.27% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders purchased 189,522 shares of company stock worth $9,157,810. Insiders own 0.34% of the company's stock.

Hedge Funds Weigh In On Boston Scientific

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. acquired a new stake in shares of Boston Scientific during the 2nd quarter valued at $5,534,781,000. Primecap Management Co. CA purchased a new position in shares of Boston Scientific in the second quarter worth approximately $2,156,233,000. Janus Henderson Group PLC lifted its position in shares of Boston Scientific by 31.0% in the 1st quarter. Janus Henderson Group PLC now owns 16,497,366 shares of the medical equipment provider's stock valued at $1,035,202,000 after acquiring an additional 3,907,981 shares in the last quarter. Amundi grew its position in Boston Scientific by 13.8% during the 1st quarter. Amundi now owns 14,122,913 shares of the medical equipment provider's stock worth $886,213,000 after purchasing an additional 1,707,754 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership raised its stake in Boston Scientific by 25.9% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 13,891,668 shares of the medical equipment provider's stock valued at $871,702,000 after purchasing an additional 2,856,040 shares during the period. Institutional investors and hedge funds own 89.07% of the company's stock.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Despite reducing forecasts, several analysts still see upside. UBS maintained a Buy rating with a $57 target, while Needham and BTIG also retained Buy ratings; Bernstein, Baird and UBS targets remain above the current share price. Analyst upgrades and downgrades
• Positive Sentiment: Management continues to express confidence in Boston Scientific’s long-term strategy, while reported revenue of approximately $5.14 billion exceeded consensus expectations. The company also said it is targeting renewed growth after the expected 2027 trough. Boston Scientific long-term investor takeaways
• Neutral Sentiment: Third-quarter adjusted EPS of $0.73 met estimates and revenue increased year over year, but the results were overshadowed by lower margins, soft segment performance and reduced full-year guidance. BSX third-quarter earnings
• Negative Sentiment: An eight-day cybersecurity outage reduced third-quarter sales by roughly $150 million and continues to disrupt operations. Management’s fourth-quarter outlook implies declining sales and adjusted EPS of $0.77–$0.79, below market expectations. Boston Scientific cybersecurity impact
• Negative Sentiment: Analyst sentiment has deteriorated: TD Cowen downgraded BSX to Hold with a $46 target, JPMorgan moved to Neutral, and Oppenheimer cut its rating to Market Perform. Zacks also added the shares to its Strong Sell list. TD Cowen rating
• Negative Sentiment: Investors are also concerned about electrophysiology and WATCHMAN weakness, China pricing pressure and expectations for largely flat growth in 2027, all of which could delay the company’s earnings recovery. BSX growth challenges through 2027

About Boston Scientific

Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide.

Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.